AHPA's monthly newsletter. Members log in to access issues of the AHPA Report.
Since the first week of March, the Food and Drug Administration (FDA) and the Federal Trade Commission (FTC) have been issuing warning letters alleging that marketers promoted a wide variety of products with claims to prevent, treat, mitigate, diagnose or cure COVID-19.
AHPA has analyzed 135 COVID-19 related warning letters issued by either FDA or FTC or by the agencies jointly between March 6, 2020, and May 11, 2020, and made available in each agency’s coronavirus information center as of May 15, 2020.
The June 2020 AHPA Report includes snapshots of global COVID-19 responses that impact the international supplement industry, FDA & FTC COVID-19 warning letters target social media and intravenous therapies, RFP for slippery elm sustainable wild harvest study, updated Hemp-CBD Status Report, and more.
The May 2020 AHPA Report includes the 2019 AHPA Annual Report, the 2020 AHPA Awards, AOAC Official Method of Analysis for cannabinoids in hemp, free cGMP webinars, AHPA advocacy in Oregon, supply chain issues, and more.
The April 2020 AHPA Report covers COVID-19, including a message from AHPA President Michael McGuffin, free resources and information for the herbal community and a summary of recent federal announcements about FDA inspections and supplement manufacturers and employees being designated as essential.
The March 2020 AHPA Report includes a discussion of proposals to make supplement regulation more efficient and effective, the Cannabis Committee's 10-year anniversary, AERs and supplement safety, postponed events and an update on international supplement regulation from IADSA.
The February 2020 AHPA Report includes a look at the recent U.S.-China trade agreement, the impact of the Coronavirus on the industry, AHPA's comments to USDA on the domestic hemp product program and the final schedule of AHPA Events at Expo West 2020.
The January 2020 AHPA Report includes class action claims reinstated on “adulterated” supplements, AHPA Events at Expo West 2020, McGuffin named Industry Leader by Nutritional Outlook, and the 2020 Hemp-CBD Supplement Congress.
The December 2019 AHPA Report includes a look back at 2019 and forward to 2020, Class action claims reinstated on “adulterated” supplements, AHPA Events at Expo West 2020, McGuffin named Industry Leader by Nutritional Outlook, and the 2020 Hemp-CBD Supplement Congress.
The November 2019 AHPA Report includes new CA Prop 65 Guidance, an overview of USDA's rule for hemp, FDA's revised draft guidance for homeopathics, happy birthday DSHEA, McGuffin keynote at HIACON and much more.
The October 2019 AHPA Report includes recent CBD advocacy, AHPA at IADSA, foreign cGMP inspection trends, nutrition labeling enforcement discretion advocacy, nutrition labeling webinar, AHPA events at SupplySide West and more.
The September 2019 AHPA Report includes guidance on herbal supplement labeling, AHPA at AOAC INTERNATIONAL, climate action in the health and nutrition industry, the glyphosate debate, GRAS: Meeting the burden of persuasion, AHPA at SupplySide West and more.
The August 2019 AHPA Report includes an analysis of FDA recall data, recent CA Prop 65 enforcement trends, the first warning letter addressing FSVP, insights from the Hemp-CBD Supplement Congress and updated guidance for hemp-CBD.
The July 2019 AHPA Report includes an open letter from AHPA President Michael McGuffin on his 20 years as AHPA President, recent CBD advocacy, AHPA's recommendations for supplement innovation, AHPA email alerts and much more.
The June AHPA Report includes recent AHPA presentations at NIH, USP, CFSAN, plus legal and regulatory updates, recent AHPA news and advocacy and much more.
The April-May AHPA Report includes strategies for TCM sustainability, legal and regulatory updates, recent AHPA news and advocacy and much more.
2021 Annual Fund Sponsors
AHPA appreciates the support of its sponsors, but does not endorse, recommend, or provide a warranty for any sponsor company, its products or services. AHPA has no responsibility for any transaction entered into with any of these companies.